SEVERANCE AGREEMENTSeverance Agreement • February 7th, 2008 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 27th day of November, 2007 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”) and John A. Tagliamonte (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 7th, 2008 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”), dated as of November 27, 2007 (the “Effective Date”), is made by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and John A. Tagliamonte (“Executive”).. This Agreement is intended to confirm the understanding and set forth the agreement between the Company and Executive with respect to Executive’s employment by the Company. In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and the Executive hereby agree as follows:
PROPRIETARY INFORMATION, INVENTIONS, AND COMPETITION AGREEMENTInformation, Inventions, and Competition Agreement • February 7th, 2008 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT, dated this 27th day of November 2007, by and between ImmunoGen, Inc., a Massachusetts corporation having its principal place of business at 128 Sidney Street, Cambridge, Massachusetts 02139 (the “Company”), and John A. Tagliamonte, an individual residing at 17 Coolidge Ave, Lexington, MA 02421 (“Employee”).
AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 7th, 2008 • Immunogen Inc • Pharmaceutical preparations
For both process and product requirements, it is assumed that the characteristics and quality of the huB4 antibody will be equivalent to the antibody currently in use for the phase I process. Any changes to the antibody manufacturing process that could compromise meeting the targeted Phase IIb specifications will not be implemented during the term of this study without mutual consent.
